Imatinib Sandoz (Imatinib)

Imatinib blocks the ATP‑binding pocket of several tyrosine kinases, including BCR‑ABL, c‑KIT and PDGFR. By locking these enzymes in an inactive state, it prevents downstream signaling that promotes malignant cell proliferation.

The specific dose and dosing schedule are determined by the prescribing clinician based on the patient’s diagnosis, disease stage, renal and hepatic function, and other individual factors. Patients should follow the prescriber’s instructions precisely.

The safety of Imatinib Sandoz in pregnancy and lactation has not been established. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To place an order, submit an enquiry on the Imatinib Sandoz product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Imatinib was the first BCR‑ABL tyrosine kinase inhibitor approved for CML and remains a standard first‑line option. Newer agents such as dasatinib or nilotinib have different potency and side‑effect profiles, but all share the same target pathway. Choice of therapy depends on disease characteristics and patient tolerance.

Imatinib Sandoz tablets should be stored at temperatures below 25 °C, in the original container, protected from moisture and direct sunlight. Do not store in bathrooms or other humid environments.

Imatinib Sandoz is taken orally, usually with a glass of water. It can be swallowed with or without food, but consistency in how it is taken (with or without meals) helps maintain stable drug levels.

Serious adverse events include severe neutropenia, hepatotoxicity, cardiac failure, pulmonary hypertension and rare interstitial lung disease. Patients should be monitored regularly for blood counts, liver enzymes and cardiac function, and any concerning symptoms reported promptly.

Imatinib Sandoz is contraindicated in patients with known hypersensitivity to imatinib or any of its excipients. Caution is advised in individuals with severe hepatic impairment, uncontrolled cardiac disease, or those who are pregnant unless the benefit justifies the risk.